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DBackground: It is unknown whether purported benefits of off-pump coronary artery bypass grafting are patient-
specific within the Society of Thoracic Surgeons National Cardiac Database or dependent on center volume or
operating surgeon.
Methods: The Society of Thoracic Surgeons National Cardiac Database was queried for all patients undergoing
nonemergency, isolated coronary artery bypass between January 1, 2005, and December 31, 2010, who had Pre-
dicted Risk of Mortality scores and participant/surgeon identifiers. Of these 876,081 patients (‘‘all sites’’),
210,469 underwent surgery at participant sites that had performed more than 300 off-pump and 300 on-pump cor-
onary artery bypass operations during the 6-year study period (‘‘high-volume sites’’). Operative mortality, stroke,
acute renal failure, mortality or morbidity, and prolonged postoperative length of stay were analyzed with condi-
tional logistic models for all sites and for high-volume sites, stratified by participant center and surgeon, and ad-
justed for 30 variables that comprise the Society of Thoracic Surgeons coronary artery bypass grafting riskmodels.
Results: Off-pump coronary artery bypass was associated with a significant reduction in risk of death, stroke,
acute renal failure, mortality or morbidity, and postoperative length of stay compared with on-pump coronary
artery bypass after adjustment for 30 patient risk factors in the overall sample. This held true within high-
volume centers. In the overall sample, there was a significant (P<.05) interaction between off-pump coronary
artery bypass and Predicted Risk of Mortality for death, stroke, acute renal failure, and mortality or morbidity.
Conclusions: Off-pump coronary artery bypass was associated with reduced adverse events compared with
on-pump coronary artery bypass after adjustment for 30 patient risk factors and center and surgeon identity.
Patients with higher Predicted Risk of Mortality scores had the largest apparent benefit. (J Thorac Cardiovasc
Surg 2013;145:1193-8)The interest in off-pump coronary artery bypass (OPCAB)
has largely been driven by the increased awareness of the
deleterious effects of cardiopulmonary bypass (CPB) and
aortic manipulation. Although an abundance of literature
comparing on-pump coronary artery bypass (ONCAB) and
OPCAB exists, the optimal surgical approach remains in
question. Although many surgeons and centers have adopted
the off-pump technique, the majority of coronary artery
bypass grafting (CABG) performed worldwide is on-pump.
In 2010, 21% of all primary CABG cases in the Society of
Thoracic Surgeons (STS) National Adult Cardiac Surgery
Database were performed with off-pump techniques.1
Several prospective, randomized trials including a meta-
analysis of these trials have not shown an in-hospital mortal-
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The Journal of Thoracic and Cartrials are limited by a relatively low sample size, especially
when trying to detect differences in an infrequent event,
such as mortality, stroke, or myocardial infarction.
Furthermore, these trials have enrolled predominantly low-
risk patients. Thus, it remains unclearwhich particular patient
populations may benefit most from OPCAB.
Numerous retrospective reviews of large databases have
demonstrated a mortality benefit for OPCAB versus
ONCAB.8-10 Such large real-world databases have the
advantage of being adequately powered to detect significant
differences in outcomes and are representative of a typical
patient population spectrum. Registry studies include
a spectrum of patients with mixed risk profiles. Ascertain-
ing which patient subgroups may benefit from OPCAB
could inform selective or increased adoption of OPCAB
for that particular risk group. Recent studies of the STS
Database have shown a mortality benefit of OPCAB for
higher-risk patients.11,12
One major criticism of both randomized controlled trials
and single-center observational analyses is that these studies
are conducted at single centers with extensive off-pump ex-
perience. It is unclear what role hospital organizational
structure in specialized centers, specialized technical skill,
or OPCAB volume may play in particular outcomes after
CABG. Relatively few studies have been conducted assess-
ing center and surgeon volume with OPCAB, and recentdiovascular Surgery c Volume 145, Number 5 1193
Abbreviations and Acronyms
ARF ¼ acute renal failure
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
CPB ¼ cardiopulmonary bypass
euroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
MM ¼ mortality or morbidity
ONCAB ¼ on-pump coronary artery bypass
OPCAB ¼ off-pump coronary artery bypass
OR ¼ odds ratio
PLOS ¼ postoperative length of stay
PROM ¼ Predictive Risk of Mortality
RR ¼ relative risk
STS ¼ Society of Thoracic Surgeons
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Dretrospective registry studies have found a mortality benefit
with OPCAB in high-volume centers.13-15
The purpose of this study is to review the relative and
absolute benefit of OPCAB versus ONCAB after adjusting
for patient preoperative risk factors within the national
database, while also controlling for surgeon and center.MATERIALS AND METHODS
Study Population
The STS National Cardiac Database was queried for all patients undergo-
ing nonemergency, isolated primary CABG between January 1, 2005, and
December 31, 2010, who had complete data fields to calculate Predictive
Risk of Mortality (PROM) scores and participant/surgeon identifiers. Of
these 876,081 patients (‘‘all sites’’), 210,469 cases underwent surgery at
participant sites that had performedmore than 300OPCABand 300ONCAB
cases during the 6-year study period (‘‘high-volume sites’’). The distributions
of patients’ preoperative characteristics in both ONCAB andOPCABgroups
are shown inTable 1. TheP values for the hypothesis that no difference exists
between 2 groups are calculated with chi-square tests for categoric variables
and Wilcoxon rank-sum tests for continuous variables.
Society of Thoracic Surgeons Predicted Risk of
Mortality
The PROM score was calculated for each patient using the risk factors
and regression coefficients from the STS 2008 model. Four PROM groups
were defined, such that the number of deaths in groups were similar (first
quartile: <1.5%; second quartile: 1.5%-3.0%; third quartile: 3.0%-
6.0%; fourth quartile:>6.0%). The mean (interquartile range) PROM
was 1.73 (0.52-1.92) overall, 1.69 (0.52-1.89) in the ONCAB group, and
1.84 (0.50-2.04) in the OPCAB group. In high-volume centers, the
PROM was 1.75 (0.52-1.94) overall, 1.74 (0.53-1.93) in the ONCAB
group, and 1.78 (0.50-1.97) in the OPCAB group.
Data Management and Statistical Analysis
Outcomes after OPCAB versus ONCAB were compared by intent-to-
treat within the entire sample and within each PROM group both descrip-
tively and by statistical models. Unplanned conversions from off-pump to
on-pump were treated as off-pump cases. The effect of OPCAB versus
ONCAB on operative mortality, stroke, acute renal failure (ARF), any mor-
tality or morbidity (MM), and prolonged postoperative length of stay1194 The Journal of Thoracic and Cardiovascular Sur(PLOS>14 days) was analyzed with conditional logistic models for all
sites and for high-volume centers, stratified by participant or by surgeon.
Unadjusted models with OPCAB as the only variable were fitted, as well
as adjusted models including all 30 patient risk factors that comprise the
STS isolated CABG2008mortality models and surgery date.16 Risk factors
for the calculation of PROM included age, body surface area, creatinine,
dialysis, ejection fraction, preoperative atrial fibrillation, congestive heart
failure and New York Heart Association classifications, chronic lung dis-
ease, cardiovascular disease, cerebrovascular accident, diabetes and type
(insulin or noninsulin dependent), number of diseased vessels, preoperative
intra-aortic balloon pump/inotropes, shock, sex, immunosuppressive treat-
ment, mitral insufficiency, percutaneous coronary intervention, peripheral
vascular disease, timing of myocardial infarction, hypertension, aortic
insufficiency, tricuspid insufficiency, aortic stenosis, left main disease,
race, and time trend. Finally, a set of conditional logistic models tested
the interaction term between the OPCAB and PROM groups to determine
whether differences between OPCAB and ONCAB depended on PROM.
To further depict the relationship between the outcomes and PROM,
generalized additive models were used with smoothing splines of
PROM. The predicted outcome rates and their pointwise 95% confidence
intervals (CIs) from these models were presented as figures to visually
discriminate between the 2 treatment groups.RESULTS
Table 2 displays the adjusted (by patient factors) and
unadjusted odds ratios (ORs) and their 95% CIs of OPCAB
versus ONCAB in the overall study sample and in high-
volume sites. Both adjusted and unadjusted models were
stratified by center. OPCAB was associated with significant
reduction in risk of death, stroke, ARF, any MM, and PLOS
greater than 14 days compared with ONCAB after adjust-
ment for 30 patient risk factors in the overall sample.Within
high-volume centers alone, OPCAB also was associated
with a significant reduction in risk of death, stroke, ARF,
any MM, and PLOS.
Table 3 displays the adjusted (by patient factors) and
unadjusted ORs and their 95% CIs of OPCAB versus
ONCAB in the overall study sample and in high-volume
sites. Both adjusted and unadjusted models were stratified
by surgeon identity. The significant reduction in risk of
death, stroke, ARF, MM, and PLOS of OPCAB compared
with ONCAB was somewhat more pronounced after strati-
fying by surgeon at all sites and high-volume centers.
In the overall sample, there was a significant (P<.05) inter-
action between OPCAB and PROM for death, stroke, ARF,
andMM, indicating that OPCABwas associatedwith a greater
reduction in these adverse events in patients with higher
PROM scores. Figure 1 displays the MM for all patients with
OPCAB versus ONCAB at varying levels of PROM, showing
the separation of lines with OPCAB having lower MM.
Table 4 shows the observed mortality and stroke in each
PROM quartile. As the PROM quartile increases, the
mortality and stroke rates are higher in both OPCAB and
ONCAB. This effect is also present with high-volume cen-
ters. Yet in all PROM quartiles, the observed rates of death
and stroke in OPCAB were lower compared with those in
ONCAB. The magnitude of that difference increased withgery c May 2013









Age, y, mean (Q1, Q3) 64.8 (57.0-73.0) 65.5 (58.0-74.0)<.0001
Male, n (%) 509,302 (73.8) 131,651 (70.7) <.0001
Black, n (%) 44,905 (6.5) 13,158 (7.1) <.0001
Body surface area, m2,
mean (Q1, Q3)
2.0 (1.8-2.2) 2.0 (1.8-2.1) <.0001
Diabetes, n (%) 275,304 (39.9) 70,462 (37.8) <.0001
Hypertension, n (%) 576,875 (83.6) 155,874 (83.7) .1908
Dialysis, n (%) 13,928 (2.0) 4676 (2.5) <.0001
CLD, n (%) 152,242 (22.1) 41,766 (22.4) <.0001
PVD, n (%) 102,094 (14.8) 30,528 (16.4) <.0001
CVD, n (%) 95,274 (13.8) 28,233 (15.2) <.0001
CVA, n (%) 46,788 (6.8) 13,950 (7.5) <.0001
Immunosuppressive
treatment, n (%)
14,615 (2.1) 4824 (2.6) <.0001
Previous CABG, n (%) 27,346 (4.0) 6096 (3.3) <.0001
Previous valve
surgery, n (%)
1910 (0.3) 618 (0.3) <.0001
Previous other cardiac
surgery, n (%)
11,340 (1.6) 3921 (2.1) <.0001
Any previous CV
surgeries 1, n (%)
30,516 (4.5) 6976 (3.7) <.0001
Prior PCI, n (%) 161,245 (23.4) 46,330 (24.9) <.0001
Acuity status ¼
elective, n (%)
319,732 (46.3) 93,384 (50.2) <.0001
MI, n (%) 309,272 (44.5) 79,618 (42.8) <.0001
Angina, n (%) 506,154 (73.4) 135,532 (72.8) <.0001
Cardiogenic
shock, n (%)
5315 (0.8) 1199 (0.6) <.0001
Resuscitation, n (%) 3201 (0.5) 775 (0.4) .0065
Arrhythmia, n (%) 53,536 (7.8) 15,1910 (8.5) <.0001
Preoperative IABP,
n (%)
40,294 (5.8) 8987 (4.8) <.0001
CHF, n (%) 98,245 (14.2) 26,960 (14.4) .0090
CHF NYHA class IV,
n (%)
27,108 (3.9) 7481 (4.0) .0767
No. of diseased
coronary
vessels ¼ 3, n (%)
546,559 (79.2) 119,220 (64.0) <.0001
Left main disease
>50%, n (%)
214,321 (31.1) 53,226 (28.6) <.0001
EF,%, mean (Q1, Q3) 51.2 (45.0-60.0) 52.0 (45.0-60.0)<.0001
Aortic stenosis, n (%) 12,221 (1.8) 4148 (2.2) <.0001
Mitral stenosis, n (%) 2399 (0.3) 691 (0.4) .0959
Tricuspid stenosis, n (%) 557 (0.1) 177 (0.1) .0461
Pulmonic stenosis, n (%) 1135 (0.2) 278 (0.1) .1822
þ Null hypothesis: variables have the same distribution (ie, same proportion for bi-
nary variables, comparable values for continuous variables) in OPCAB and ONCAB
groups. Wilcoxon rank-sum test is used for continuous variables, and Pearson’s
chi-square test is used for categoric variables. ONCAB, On-pump coronary artery
bypass; OPCAB, off-pump coronary artery bypass; CLD, chronic lung disease;
PVD, peripheral vascular disease; CVD, cardiovascular disease; CVA, cerebrovascu-
lar accident; CABG, coronary artery bypass grafting; CV, cardiovascular; PCI, percu-
taneous coronary intervention; MI, myocardial infarction; IABP, intra-aortic balloon
pump; CHF, congestive heart failure; NYHA, New York Heart Association; EF,
ejection fraction.
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the group with the lowest PROM and increased to 25.8% in
the group with the highest PROM. Large-volume centers
had a slightly lower rate of death than lower-volume cen-
ters. The relative lower rates of death and stroke with OP-
CAB versus ONCAB were similar in high-volume centers
compared with all centers.
DISCUSSION
This retrospective review of the STS National Adult Car-
diac Database analyzed 876,081 patients who underwent
coronary bypass grafting between January 1, 2005, and
December 31, 2010. Of these, 210,469 patients underwent
operation at high-volume centers where more than 300
OPCAB and ONCAB cases were performed during this
time period. This is the largest series to date to examine out-
comes after CABG with and without CPB.
In this intent-to-treat analysis, OPCAB was associated
with reduced adverse events compared with ONCAB after
adjustment for 30 patient risk factors.OPCABwas associated
with a significant reduction in risk of death, stroke, ARF, any
MM, and prolonged PLOS compared with CABG on CPB.
Numerous prospective, randomized trials have not shown
an in-hospital mortality advantage for OPCAB versus ON-
CAB, although these trials have shown an advantagewith re-
gard to transfusion requirements, myocardial enzyme
release, intensive care unit and hospital length of stay, dura-
tion of mechanical ventilation, and cost.2-6 In the largest
multicenter randomized trial to date comparing OPCAB
with ONCAB (4752 patients) at 79 centers in 19 countries,
Lamy and colleagues17 found no difference in the 30-day
rate of primary composite outcome of death, myocardial in-
farction, stroke, or renal requiring dialysis. OPCAB was as-
sociated with reduced rates of transfusions, reoperation for
perioperative bleeding, respiratory complications, and acute
kidney injury, but resulted in an increased risk of early revas-
cularization. The trial was conducted by surgeons with ex-
pertise in OPCAB or ONCAB, yet the majority of patients
were ofmixed-risk (European System for Cardiac Operative
Risk Evaluation [euroSCORE] 3-5) and ejection fraction
>50%. In a meta-analysis of 37 randomized trials (3369 pa-
tients), no significant differences were found for 30-day
mortality between OPCAB and ONCAB (OR, 1.02; 95%
CI, 0.58-1.80).7 As opposed to large-scale observational
studies, failure to show any differences in randomized trials
can be attributed to low sample size, which can increase the
probability of a type II error, as well as a predominance of
low- or intermediate-risk patients.
In the present large retrospective analysis, within all
PROM quartiles, OPCABwas associated with a significantly
reduced risk of death and stroke. Moreover, the magnitude of
the apparent risk reduction increased with increasing PROM.
As such, the perceived benefits of OPCAB may become
more apparent in high-risk patients, especially those withdiovascular Surgery c Volume 145, Number 5 1195
TABLE 2. Off-pump versus on-pump in the overall study sample and in large centers, adjusted (by patient factors), and unadjusted odds ratios and
their 95% confidence intervals
Outcome
Models stratified by center identity
All sites High-volume sites
Not adjusted by patient RF Adjusted by patient RF Not adjusted by patient RF Adjusted by patient RF
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Operative mortality 0.95 (0.91-1.00) .0709 0.89 (0.84-0.94) <.0001 0.86 (0.79-0.93) <.0001 0.84 (0.77-0.91) <.0001
Stroke 0.66 (0.62-0.71) <.0001 0.66 (0.62-0.71) <.0001 0.66 (0.60-0.72) <.0001 0.66 (0.60-0.73) <.0001
Renal failure 0.83 (0.80-0.86) <.0001 0.80 (0.77-0.84) <.0001 0.82 (0.77-0.86) <.0001 0.82 (0.78-0.87) <.0001
Operative MM 0.78 (0.77-0.80) <.0001 0.78 (0.76-0.79) <.0001 0.77 (0.74-0.79) <.0001 0.78 (0.75-0.80) <.0001
Prolonged PLOS 0.82 (0.79-0.84) <.0001 0.77 (0.74-0.79) <.0001 0.79 (0.76-0.83) <.0001 0.77 (0.73-0.80) <.0001
Both adjusted and unadjusted models were stratified by center. Adjusted analyses adjust for patient-level characteristics; the list of factors is the same as the STS 2008 isolated
CABG model, plus surgery date. RF, Risk factor; OR, odds ratio; CI, confidence interval; MM, mortality or morbidity; PLOS, postoperative length of stay.
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and advanced atheromatous disease of the ascending aorta
subject to aortic clamping, manipulation, and cannulation
with CPB. Large-scale registries and observational studies
are sufficiently powered to detect significant differences
in adverse outcomes across a broad patient population and
especially high-risk patients. Hannan and colleagues,8 in
49,830 patients from the New York State registry who
underwent a risk-adjusted analysis (Cox proportional haz-
ard models and propensity analysis), showed that patients
undergoing OPCAB had a significantly lower 30-day mor-
tality than those undergoing ONCAB (adjusted OR, 0.81;
95% CI, 0.68-0.97; P¼ .0022).8 In another large California
registry study, Li and colleagues9 also demonstrated
a significant reduction in propensity-adjusted operative
mortality with OPCAB compared with ONCAB (2.59%;
95% CI, 2.52-2.67 vs 3.22%, 95% CI, 3.17-3.27). An
intention-to-treat retrospective analysis of 42,477 patients
from the STS National Database showed a reduction in
risk-adjusted operative mortality (adjusted OR, 0.83;
P¼ .03), as well as numerous morbidity outcomes favoring
patients undergoing OPCAB.11 To the contrary, assessing
63,000 patients in the Nationwide Inpatient Sample admin-
istrative (rather than clinical) database, Chu and col-
leagues18 found no difference in hospital mortality
between OPCAB and ONCAB (3.0% vs 3.2%, P ¼ .14).TABLE 3. Off-pump versus on-pump in the overall study sample and in larg




Not adjusted by patient RF Adjusted by patie
OR (95% CI) P value OR (95% CI) P
Operative mortality 0.93 (0.88-0.99) .0231 0.85 (0.80-0.90) <
Stroke 0.63 (0.58-0.68) <.0001 0.63 (0.58-0.68) <
Renal failure 0.79 (0.76-0.83) <.0001 0.77 (0.73-0.81) <
Operative MM 0.77 (0.75-0.79) <.0001 0.77 (0.75-0.79) <
Prolonged PLOS 0.83 (0.80-0.86) <.0001 0.77 (0.74-0.80) <
Both adjusted and unadjusted models were stratified by surgeon identity. Adjusted analyses
isolated CABG model, plus surgery date. RF, Risk factor; OR, odds ratio; CI, confidence
1196 The Journal of Thoracic and Cardiovascular SurIn retrospective series, more favorable outcomes have
been reported after OPCAB compared with ONCAB in pa-
tients with left ventricular dysfunction, left main disease,
end-stage renal disease on dialysis, previous sternotomy, ad-
vanced age, previous stroke, and female gender.11,19-21 In
a large retrospective cohort (14,766 patients), Puskas and
colleagues12 reported that patients in the highest risk quartile
had a significant reduction in hospital mortality with OP-
CAB compared with ONCAB (3.2% vs 6.7%; P<.0001;
OR, 0.45; 95% CI, 0.33-0.63; P<.0001). There was no dif-
ference in operativemortality betweenOPCABandONCAB
for patients in the lower 2 risk quartiles. However, patients
with an STS predicted risk ofmortality>2.5% had an appar-
ent survival advantage with OPCAB. That study provides
further support that OPCAB may disproportionately benefit
high-risk patients. The apparent mortality benefit shown for
OPCAB in large retrospective analyses seems to be driven by
a disproportionate benefit experienced by the higher-risk
patients within real-world databases.
As randomized trials have begun to focus on higher-risk
patients, results havedemonstratedmore favorable outcomes
for OPCAB comparedwith ONCAB. In a trial byMoller and
colleagues22 (the Best Bypass Surgery Trial), 341 high-risk
patients (euroSCORE 5) underwent multivessel OPCAB
orONCAB.22 The difference in event rates for the composite
of major adverse cardiac and cerebrovascular events at 30e centers, adjusted (by patient factors), and unadjusted odds ratios and
atified by surgeon identity
High-volume sites
nt RF Not adjusted by patient RF Adjusted by patient RF
value OR (95% CI) P value OR (95% CI) P value
.0001 0.76 (0.68-0.85) <.0001 0.75 (0.68-0.84) <.0001
.0001 0.63 (0.55-0.71) <.0001 0.63 (0.56-0.72) <.0001
.0001 0.71 (0.65-0.76) <.0001 0.73 (0.67-0.79) <.0001
.0001 0.72 (0.70-0.75) <.0001 0.74 (0.71-0.77) <.0001
.0001 0.77 (0.73-0.82) <.0001 0.74 (0.70-0.79) <.0001
adjust for patient-level characteristics; the list of factors is the same as the STS 2008
interval; MM, mortality or morbidity; PLOS, postoperative length of stay.
gery c May 2013
FIGURE 1. Predicted risk of MM by PROM in OPCAB and ONCAB.
*Y-axis shows the predicted event rates and CIs from generalized additive
models fitted with MM as outcome and PROM as the only predictor.
CABG, Coronary artery bypass grafting; CPB, cardiopulmonary bypass;
OPCAB, off-pump coronary artery bypass; STS, Society of Thoracic
Surgeons.
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Ddays was not statistically significant (15% vs 18%; relative
risk [RR], 0.83; 95%CI, 0.52-1.34), but therewas a trend to-
ward reduced all-cause 30-day mortality in the OPCAB
group (3.4% vs 6.7%; RR, 0.51; 95% CI, 0.19-1.34). A
lack of statistical difference may have been related to the
small sample size. In an interim analysis of 411 high-risk pa-
tients in a multicenter, prospective, randomized trial (on-off
study), Lemma and colleagues23 reported that the composite
primary end point (operative mortality, myocardial infarc-
tion, stroke, renal failure, reoperation for bleeding, and adult
respiratory distress syndrome) was significantly lower in the
OPCABgroup (5.8% vs 13.3%,P¼ .010).23All patients en-




No. case No. operation % No. case No. operation
Mortality
1 721 122,355 0.6 2977 466,405
2 746 35,010 2.1 2898 131,147
3 762 18,788 4.1 2877 63,606
4 881 9985 8.8 2878 28,785
Stroke
1 641 122,355 0.5 3594 466,405
2 404 35,010 1.2 2375 131,147
3 329 18,788 1.8 1622 63,606
4 233 9985 2.3 933 28,785
PROM, Predicted Risk of Mortality.
The Journal of Thoracic and Carof 8, and the operations were performed by surgeons with
extensive training and experience in OPCAB and ONCAB
techniques, a feature lacking in some previous trials not
showing a difference.
The findings in the present analysis of the STS National
Cardiac Database show that adjusted risk of stroke was
decreased with OPCAB compared with ONCAB. There
have been no randomized prospective trials that have shown
a statistically significant reduction in stroke with OPCAB
compared with ONCAB. However, numerous large retro-
spective analyses have shown that OPCAB may be associ-
ated with a reduced risk-adjusted incidence of stroke
compared with ONCAB.8,20,24 In a recent meta-regression
analysis of 59 randomized trials encompassing 8961 pa-
tients, Afilalo and colleagues25 showed a significant 30%
reduction in the occurrence of postoperative stroke with
OPCAB (RR, 0.70; 95% CI, 0.49-0.99). Although the
mechanisms responsible for the observed reduction in post-
operative stroke have not been well defined, eliminating
aortic manipulation with cannulation and application of
a crossclamp, assessing aortic atherosclerosis by intraoper-
ative epiaortic ultrasonography, and using clampless proxi-
mal anastomotic devices may decrease the number of
intraoperative embolic events. The STS Database does not
have data on the rate of use of clampless techniques until
the most recent version of the database, which is after the
end of our study period.
In the present study, the advantage of OPCAB over
ONCAB in reduction of mortality, stroke, ARF, MM, and
PLOS changed only minimally after stratification by center
and by surgeon. This indicates that the benefit of OPCAB
is largely independent of centers and surgeons within the
STS National Cardiac Database. The relative reduction of
risk of death and stroke with OPCAB versus ONCAB was
similar in high-volume centers compared with all centers
across all PROMquartiles. Konety and colleagues14 assessed
the effect of surgical volume on outcomes after OPCAB
(n ¼ 26,011) and ONCAB (n ¼ 99,344) in 124 Californiaby Predicted Risk of Mortality groups
Patients from large centers
Off-pump On-pump
% No. case No. operation % No. case No. operation %
0.6 269 53,295 0.5 516 87,251 0.6
2.2 300 14,798 2.0 535 25,096 2.1
4.5 289 7749 3.7 560 12,503 4.5
10.0 338 4041 8.4 558 5736 9.7
0.8 293 53,295 0.5 746 87,251 0.9
1.8 185 14,798 1.3 487 25,096 1.9
2.6 148 7749 1.9 328 12,503 2.6
3.2 94 4041 2.3 199 5736 3.5
diovascular Surgery c Volume 145, Number 5 1197
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For hospitals in the highest percent OPCABvolume quartile,
adjusted mortality and complication rates were significantly
lower compared with ONCAB (OR, 0.50; 95% CI, 0.41-
0.61; P<.001). However, in the lowest percent OPCAB vol-
ume quartile, outcomes between OPCAB and ONCABwere
similar. In a recent study examining theNationwide Inpatient
Sample database from 2003 to 2007, Lapar and colleagues15
showed that therewas an estimated 5% decrease in the abso-
lute probability of death among 270,230 patients undergoing
OPCAB when performed by surgeons with the highest vol-
ume, compared with a 3% decrease in 439,253 patients
undergoing ONCAB. Yet the effect of surgeon volume was
significantly less than other operative and patient risk factors,
questioning the contribution of surgeon volume toward mor-
tality. Although the benefit ofOPCABmaybe increasedwith
higher relative hospital volume, it can also be safely per-
formed across a variety of hospitalswith differing experience
levels. In addition to surgeon skill, hospital organizational
structures, such as skilled first and second assistants, surgical
technicians, operating room nurses, intensive care unit re-
sources, and anesthesia personnel, may be important factors.Study Limitations
The present study is limited by its retrospective, observa-
tional nature. Despite adjusting for 30 patient preoperative
factors, as well as surgeon and hospital identity, there is
potential for residual confounding from factors not captured
in the STS Database. Although the STS National Database
collected data across multiple institutions, the expertise
and interest may vary across centers. Major limitations of
retrospective analyseswithin the STSDatabase are selection
bias in the choice of OPCAB versus ONCAB and potential
underreporting of unplanned conversion from off-pump to
on-pump. In addition, the outcomes evaluated in our analy-
sis are short-term outcomes, and long-term outcomes, such
as rates of revascularization, freedom from symptoms, and
long-termmortality, were not evaluated in our study.Despite
the rigorous nature of the data collected within the STS
Database, itmay not be possible to adjust for all confounding
variables, known and unknown, that may affect the choice of
surgical procedure and patient outcomes.CONCLUSIONS
In this analysis of the STS National Databse, OPCAB
was associated with reduced risk of death, stroke, acute re-
nal failure, mortality or morbidity, and prolonged length of
stay compared with ONCAB after adjustment for 30 patient
risk factors and stratifying for both center and surgeon iden-
tity. OPCAB had a significantly greater reduction in these
adverse events in patients with higher PROM scores. The
benefit of OPCAB, therefore, may be more apparent in
high-risk patients.1198 The Journal of Thoracic and Cardiovascular SurReferences
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